NVAX · Novavax Inc · Documents

Feb 27

Earnings call

Q4 2024 earnings call

Feb 27

Current report 8-K

Financial results

Feb 27

Annual report 10-K FY2024, ended Dec 31

Annual report for FY2024

Revenue $682.16M ▼ 30.7% Net loss $187.5M Diluted EPS -$1.23

Jan 13

Current report 8-K

Financial results, Regulation FD disclosure

Dec 30

Current report 8-K

Completed an acquisition or sale of assets

Dec 18

Current report 8-K Events of Dec 12

Entered into a material agreement

Dec 4

Current report 8-K Events of Dec 3

Entered into a material agreement

Nov 20

Current report 8-K Events of Nov 19

Regulation FD disclosure

Nov 12

Earnings call

Q3 2024 earnings call

Nov 12

Current report 8-K

Financial results

Nov 12

Current report 8-K Events of Nov 11

Regulation FD disclosure, Other events

Nov 12

Quarterly report 10-Q FY2024 Q3, ended Sep 30

Quarterly report for FY2024 Q3

Revenue $84.51M ▼ 54.8% Net loss $121.3M Diluted EPS -$0.76

Nov 5

Current report 8-K Events of Nov 1

Entered into a material agreement, Ended a material agreement

Oct 16

Current report 8-K

Regulation FD disclosure, Other events

Oct 3

Current report 8-K Events of Oct 2

Regulation FD disclosure

Aug 8

Earnings call

Q2 2024 earnings call

Aug 8

Current report 8-K

Financial results

Aug 8

Quarterly report 10-Q FY2024 Q2, ended Jun 30

Quarterly report for FY2024 Q2

Revenue $415.48M ▼ 2.1% Net income $162.38M ▲ 179.9% Diluted EPS $0.99 ▲ 70.7%

Jun 14

Current report 8-K Events of Jun 13

Director or officer change, or executive pay, Shareholder vote results

Jun 6

Current report 8-K

Regulation FD disclosure, Other events

Jun 5

Proxy statement DEFA14A

Proxy statement

May 23

Current report 8-K Events of May 20

Director or officer change, or executive pay

May 13

Current report 8-K Events of May 10

Entered into a material agreement, Unregistered sale of equity

May 10

Earnings call

Q1 2024 earnings call

May 10

Current report 8-K

Financial results

May 10

Quarterly report 10-Q FY2024 Q1, ended Mar 31

Quarterly report for FY2024 Q1

Revenue $93.86M ▲ 15.9% Net loss $147.55M Diluted EPS -$1.05

Apr 29

Proxy statement DEF 14A Meeting Jun 13, 2024

Proxy statement

Apr 29

Annual report to holders ARS

Annual report to holders

Apr 29

Proxy statement DEFA14A

Proxy statement

Apr 26

Current report 8-K Events of Apr 22

Charter or bylaw amendment, or fiscal year change

Mar 26

Current report 8-K Events of Mar 22

Entered into a material agreement

Feb 28

Earnings call

Q4 2023 earnings call

Feb 28

Current report 8-K

Financial results

Feb 28

Annual report 10-K FY2023, ended Dec 31

Annual report for FY2023

Revenue $983.71M ▼ 50.4% Net loss $545.06M Diluted EPS -$5.41

Feb 22

Current report 8-K Events of Feb 16

Entered into a material agreement, Ended a material agreement

Jan 31

Current report 8-K Events of Jan 30

Exit or restructuring costs

Jan 8

Current report 8-K

Financial results, Regulation FD disclosure

Dec 5

Current report 8-K

Other events

Nov 17

Current report 8-K Events of Nov 13

Director or officer change, or executive pay, Regulation FD disclosure

Nov 9

Earnings call

Q3 2023 earnings call

Nov 9

Current report 8-K

Financial results

Nov 9

Quarterly report 10-Q FY2023 Q3, ended Sep 30

Quarterly report for FY2023 Q3

Revenue $186.99M ▼ 74.5% Net loss $130.78M Diluted EPS -$1.26

Nov 2

Current report 8-K/A

Shareholder vote results

Oct 3

Current report 8-K

Regulation FD disclosure

Aug 8

Current report 8-K

Other events

Aug 8

Current report 8-K

Entered into a material agreement, Ended a material agreement, Unregistered sale of equity

Aug 8

Earnings call

Q2 2023 earnings call

Aug 8

Current report 8-K

Financial results

Aug 8

Quarterly report 10-Q FY2023 Q2, ended Jun 30

Quarterly report for FY2023 Q2

Revenue $424.43M ▲ 128.3% Net income $58.01M Diluted EPS $0.58

Jul 11

Current report 8-K

Director or officer change, or executive pay, Shareholder vote results